Business EconomyPosted at: Jun 5 2025 10:15PM


Dr Reddy’s Lab partners with Alvotech to Co-Develop & commercialize Biosimilar Candidate

Hyderabad, June 5 (UNI) Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy’s Laboratories Ltd, on Thursday announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets.
Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancerTypes, Hyderabad based pharma giant said in a release here.
In 2024, worldwide sales of Keytruda were US$29.5 billion.
The collaboration combines Dr.Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby speeding up the development process and extending the global reach for this biosimilar candidate.
Under the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.
“We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy’s. This agreement demonstrates Alvotech’s ability to leverage its dedicated R& D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patient’s world-wide,” said Róbert Wessman, chairman and CEO of Alvotech.
Dr Reddy’s CEO Erez Israeli said “We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of themost critical therapies in immuno-oncology.”
UNI KNR BD
Tags: #Dr Reddy’s Lab partners with Alvotech to Co-Develop & commercialize Biosimilar Candidate
More News

OHPC signs agreement with WAPCOS for management consultancy services of 600 MW UIPSP

06 Jun 2025 | 7:12 PM

Bhubaneswar, June 6 (UNI) Odisha Hydro Power Corporation Ltd (OHPC) and WAPCOS Ltd on Friday signed an agreement for project management consultancy services for the 600 MW Upper Indravati Pumped Storage Project (UIPSP) at Mukhiguda.

see more..

Kamdhenu to scale up branded colour coated sheets capacity by 25 pc in Telangana plant

06 Jun 2025 | 6:18 PM

Hyderabad, June 6 (UNI) In a strategic move to strengthen its market share and presence of its brand 'Kamdhenu Colour Max Sheet’ in Telangana, Kamdhenu Limited, India’s largest manufacturer and seller of branded TMT Bars in retail, on Friday announced plans to scale up its Siddipet Plant manufacturing capacity by 25 percent within a year.

see more..
Rupee up by 16 paise against USD

Rupee up by 16 paise against USD

06 Jun 2025 | 5:52 PM

Mumbai, June 5 (UNI) Rupee on Friday appreciated by 16 paise to close at 85.63 on weak demand for US Dollar by bankers and importers, a forex trader said.

see more..

Kottayam-Kochi Rubber Market Rates

06 Jun 2025 | 5:51 PM

Kottayam, June 6 (UNI) Following were the Rubber Market rates announced by the Rubber Board here today per quintal.

see more..
RBI cuts repo rate by 50 bps to 5 50 pc

RBI cuts repo rate by 50 bps to 5 50 pc

06 Jun 2025 | 5:29 PM

Mumbai, June 6 (UNI) The Reserve Bank of India (RBI) on Friday in its second bi-monthly monetary policy of FY26. cut the repo rate by 50 basis points (bps) to 5.50 pc from 6.00 pc earlier. This is the central bank’s third consecutive repo rate cut.

see more..